Is Running Good for Perimenopause Depression?
Running raises BDNF, serotonin, and endorphins to fight perimenopause depression. See the evidence comparing running to medication and how to start when motivation is low.
Depression in Perimenopause: A Neurobiological Picture
Depression during perimenopause is not simply a reaction to life stress or the emotional weight of midlife change, though those factors play a role. It is fundamentally a neurobiological condition driven by the same hormonal shifts that cause hot flashes and brain fog. Estrogen supports serotonin synthesis, protects monoamine oxidase activity, and upregulates serotonin receptor density. As estrogen declines in perimenopause, all three of these functions are compromised. The result is a serotonin-insufficient environment in which the neurochemical substrate for sustained positive mood is weakened. Progesterone's conversion to allopregnanolone, a neurosteroid that calms the nervous system via GABA receptors, is also reduced. This means that two of the primary mood-stabilising neurochemical systems are simultaneously undermined. Sleep disruption from night sweats and early waking adds its own layer to the picture by impairing emotional regulation in the prefrontal cortex and increasing amygdala reactivity, which makes negative emotional stimuli feel more threatening and reduces the capacity to experience pleasure. Running addresses multiple nodes in this neurobiological network simultaneously, which is why it is among the most effective physical interventions for perimenopausal depression and why its antidepressant effects are well documented in research.
BDNF: The Brain Fertiliser That Running Produces
Brain-derived neurotrophic factor, commonly abbreviated as BDNF, is one of the most important molecules in the biology of depression and its treatment. BDNF promotes the growth of new neurons in the hippocampus, strengthens synaptic connections, protects existing neurons from stress-related damage, and supports the signalling efficiency of serotonin and dopamine systems. Depression is associated with consistently low BDNF levels and reduced hippocampal volume, and several antidepressant medications work in part by increasing BDNF production. Running is among the most potent known stimulators of BDNF synthesis. A single bout of aerobic exercise increases circulating BDNF levels substantially, with the magnitude proportional to exercise intensity within the moderate to vigorous range. Chronic running, maintained over weeks and months, produces sustained elevations in hippocampal BDNF that lead to measurable increases in hippocampal volume, as demonstrated in multiple neuroimaging studies. This is particularly relevant during perimenopause because estrogen withdrawal is associated with hippocampal vulnerability and reduced BDNF signalling. Running effectively substitutes for some of the BDNF-supportive function that estrogen previously provided. For women who are not on HRT, this makes running one of the most biologically rational responses to perimenopausal depression available outside pharmacological treatment.
Evidence Comparing Running to Antidepressant Medication
The comparison between exercise and antidepressant medication is one of the most studied questions in lifestyle psychiatry. A landmark randomised controlled trial published in the Archives of Internal Medicine assigned adults with major depressive disorder to either aerobic exercise, sertraline, or a combination of both. After 16 weeks, all three groups showed equivalent reductions in depression symptoms. Critically, a 10-month follow-up showed that those who maintained their exercise habit had significantly lower relapse rates than the medication group, suggesting that exercise produces more durable antidepressant effects when continued. Multiple subsequent meta-analyses and systematic reviews have replicated the finding that exercise, at sufficient dose and intensity, produces antidepressant effects comparable to low to moderate dose antidepressant medication for mild to moderate depression. For perimenopause specifically, the relevant distinction is that most antidepressants do not address the underlying hormonal cause of depression. They manage symptoms by modifying neurotransmitter reuptake while estrogen deficiency continues to destabilise the neurochemical environment. Running, by contrast, raises BDNF, cortisol regulation, and serotonin tone in ways that interact with the hormonal environment rather than simply overriding it. The combination of running with HRT, which restores the estrogen support that antidepressants cannot provide, often produces better outcomes than either antidepressants or exercise alone.
Starting to Run When Depression Has Killed Your Motivation
The central challenge of using running to treat depression is that depression specifically impairs the motivation, energy, and self-efficacy that running requires. Women with moderate to severe perimenopausal depression often describe it as physically impossible to lace up and get out the door, not because they do not want to feel better but because the neurochemical environment of depression suppresses the dopamine-driven motivation circuits needed to initiate novel behaviour. The most evidence-supported strategy for overcoming this is implementation intentions combined with extremely small starting targets. Rather than planning to run, decide exactly when and where you will walk out the door, even if the initial plan is only five minutes. Research on behaviour change in depression consistently shows that the most effective intervention is reducing the initiation threshold to near zero. Five minutes of easy jogging is a full success. The neurochemical lift from even a short run, including acute endorphin and endocannabinoid release, is often enough to make the next session feel slightly more accessible. Building on small successes produces better long-term adherence than ambitious targets that fail repeatedly. Having a running partner who will appear at your door removes the initiation decision from the equation entirely, which is why accountability partners are particularly effective for exercise in depression.
Running Intensity and Frequency for Antidepressant Effects
Research on the dose-response relationship between running and depression suggests that the antidepressant threshold requires moderate intensity sustained for at least 20 to 30 minutes per session, on at least three days per week. Below this threshold, running may still improve mood acutely but is unlikely to produce the sustained neurobiological changes that reverse depression. Moderate intensity for running is broadly equivalent to a pace where breathing is noticeably elevated, conversation is possible but requires effort, and perceived exertion is around 5 to 6 on a 10-point scale. This corresponds approximately to 60 to 75 percent of maximum heart rate. Running at this intensity for 30 minutes, three to four times per week, has been shown in multiple trials to produce significant antidepressant effects within four to six weeks. The total weekly volume of 90 to 150 minutes of moderate running appears to be the minimum effective dose. More than this is not necessarily better for depression outcomes, and very high volumes can increase cortisol in ways that are counterproductive. Women in perimenopause who are also dealing with fatigue, which often coexists with depression, may find that starting with 20-minute sessions three times per week and building from there produces better adherence than immediately targeting 30-minute sessions.
Running as Part of a Broader Treatment Strategy
Running is one of the most powerful tools in the non-pharmacological arsenal for perimenopausal depression, but it works best as part of a broader approach rather than in isolation. The hormonal driver of perimenopausal depression, estrogen insufficiency, is not directly addressed by running. HRT, by restoring a more stable estrogen environment, addresses the root cause and creates a neurochemical context in which running's antidepressant mechanisms can function more effectively. Women who combine HRT with regular running often report that both mood and physical energy improve substantially faster than with either intervention alone. Psychotherapy, particularly cognitive behavioural therapy and acceptance-based approaches, addresses the cognitive patterns of depression that running does not reach, including catastrophic thinking, self-criticism, and behavioural withdrawal. Adequate protein intake supports neurotransmitter synthesis, since serotonin and dopamine are built from amino acids including tryptophan and tyrosine, and protein deficiency impairs the neurochemical processes that running is trying to stimulate. Social connection, which is both a symptom target and a treatment element, can be built into running through group or partner formats. Women who approach perimenopausal depression through this multi-pronged framework, addressing the hormonal, neurochemical, behavioural, cognitive, and social dimensions simultaneously, consistently report the most sustained and comprehensive recovery.
Related reading
Get your personalized daily plan
Track symptoms, match workouts to your day type, and build a routine that adapts with you through every phase of perimenopause.